HeyJaredBen Fidler
- Indexed articles, last 90 days
- 6
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Construction Dive
- Top 1M sites
- Earliest in this view
- Jul 7, 2026
Latest articles
BioPharma Dive Trendline on Radiopharmaceuticals (opens the original)
Read excerpt
More than a dozen startups are developing drugs that deliver a dose of radiation directly to tumors. Here’s where they stand, and why their progress is worth watching. Editor’s note: This story was published in August 2023 and, since then, the radiopharmaceuticals field has advanced quickly. We’re including this story in the trendline you’re reading as it provides a useful snapshot of when the field started to take off. When the Food and Drug Administration approved a new prostate cancer drug in
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push (opens the original)
Read excerpt
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights. AstraZeneca is getting a closer look at one of the most closely watched drugs in oncology research, announcing Monday a substantial equity investment in the medicine’s developer, Summit Therapeutics, as well as a broad alliance to accelerate its progress. Per deal terms, AstraZeneca will invest $2 billion in Sum
Alnylam plunges as earnings deliver ‘one-two punch’ (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Alnylam Pharmaceuticals lost nearly 30% — or close to $12 billion — of its market value after the company surprised investors by lowering financial forecasts for its most important drug franchise by $200 million. The RNA-focused biotechnology company had previously predicted those drugs, the transthyretin amyloidosis medications Amvuttra and Onpattro,
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround. The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to
Scribe secures $129M in a rare gene editing IPO (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 million in the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million shares at $15 apiece, topping projections set earlier this week. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol "SCTX
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For Construction Dive, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.